>>>>>>>>>>>>>>>>>>>Promote your Website with BidVertiser. Get $20 in FREE traffic.<<<<<<<<<<<<<<<<<<<<
Find What You Search! Professional Industry and Manufacturing Directory - Forexmarket.site is delivering over 4 million unique visitors from organic and paid web traffic sources such as Google Ads and other paid advertising networks everyday. Search Forexmarket and Worldbank.nu directory, covering millions of industry hardware, products and services. Search our industry directory to view highlights from Amazon.com stores for safe transaction, purchase and worldwide delivery. Don't miss out to read our latest best-selling politics e-book, about the most powerful woman in politics, a series of best political leader biographies at Amazon.com Kindle: The Biography of Angela Merkel - Something About Great Leadership. Moreover, our online stock trading platform provider offer here $5000 trading bonus to sophisticated investors, don't miss out on that. Get the latest day trading incentives and tips on best dividend stocks: Forex Market Day Trading; WhatsApp Group Invite. Welcome to add your website free of charge, submit your company information. We do manage other websources such as the Luxury Brands Reviews website with honest reviews for luxury brands awareness and trust to ensure the very best customer experience every time. Make your best online shopping experience here! Thank you for visit The Forexmarket.
Oragenics, Inc. (NYSE:OGEN) is developing TerraCoV2, a vaccine candidate against SARS-CoV-2 (the virus that causes COVID-19) that is licensed from the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine candidate is targeted against the prefusion spike (S) protein found on the surface of SARS-CoV-2 (more details below). Since acquiring the rights to the vaccine candidate earlier in 2020, Oragenics has completed the creation of the antigen producing CHO cell line, with purification methods currently under development. In addition, we anticipate the company announcing a deal for an adjuvant to be used with the vaccine in the first quarter of 2021. We also anticipate the completion of various preclinical studies during the first quarter of 2021 that will include mouse immunogenicity studies and hamster challenge studies. Currently, we estimate that the company will file an IND for TerraCoV2 by the end of the second quarter of 2021, with a Phase 1 clinical trial initiating in the third quarter of 2021. The Phase 1 trial will likely take 8-10 weeks to perform and will examine a number of dosing parameters for the vaccine, including the potential for a single dose, which is in contrast to the two doses necessary for the leading vaccine candidates. A successful Phase 1 trial could potentially lead to a Phase 2/3 trial initiating by the end of 2021.
Oragenics, Inc. is focused on the discovery, development and commercialization of a range of technologies associated with oral health, antibiotics and other general health benefits.
Learn more! Visit Publisher Site link above
$5,000 In One Day?! | What Penny Stocks to Buy Next!